|0.158|| +0.0081 / +5.40%|
NovaBay Pharmaceuticals, Inc. engages in developing compounds to address the unmet therapeutic needs. It operates through the following segments: Dermatology, Ophthalmology, Urology, Wound Care, and Others. The Dermatology segment includes all aspects of its business around the dermatology arena including the collaboration with Galderma and their impetigo clinical trial. The Ophthalmology segment includes Avenova and its clinical trial on ophthalmology which it was conducting on its own. The Urology segment covers its urinary catheter encrustation and blockage (UCBE) trials. The Wound Care segment encompasses the business around its NeutroPhase product. The Others segment are immaterial and are shown as an aggregate. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.
|Mark M. Sieczkarek||Chairman, President & Chief Executive Officer|
|Thomas J. Paulson||CFO, CAO, Secretary & Treasurer|
|Roy J. Wu||Senior VP-Business & Corporate Development|
|David W. Stroman||Senior Vice President-Ophthalmology|
|Glenn Moro||Vice President-Sales & Marketing|